PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28424891-14	2017	Overlapping toxicities prevented the escalation of selumetinib to its recommended phase II monotherapy dose of 75 mg BID.	AZD 6244	51-62	BH3 interacting domain death agonist	Homo sapiens	117-120	
29136201-13	2018	Selumetinib 75 mg BID plus docetaxel 60 mg/m2 was not tolerated in this patient population.	AZD 6244	0-11	BH3 interacting domain death agonist	Homo sapiens	18-21	
28264648-6	2017	Part A of the study (dose escalation) evaluated safety, tolerability, PK, and maximum tolerated dose (MTD) of selumetinib twice daily (BID) with docetaxel 75 mg/m2 or dacarbazine 1000 mg/m2 administered every 21 days.	AZD 6244	110-121	BH3 interacting domain death agonist	Homo sapiens	135-138